Although anti-C5a monoclonal antibodies have demonstrated efficacy in severe conditions such as sepsis and ARDS, their single-target nature and comprehensive inhibition of the upstream complement pathway may pose infection risks. This evidence concerns the gene C5 and Sepsis.